Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
What is driving the cost trend for employers
Radad K, Gille G, Rausch WD
10.3969/j.issn.1674-3865.2012.05.010 Summary Keywords Schisandra chinensis, liver injury, Chinese medicine, preclincal study, meta-analysis Citation Huang B-H, Lv B-H, Wu D-J, Xiong F-Y, Li Y-B, Lu Y-P and Lv W-L (2025) Efficacy of Schisandra chinensis in liver injury: a systematic review and preclinical meta-analysis
However, individual results vary, and effectiveness depends on factors such as adherence, lifestyle habits, dosage, and overall health
Cellcept (mycophenolate mofetil): Used to prevent organ rejection, requires a 6-week deferral
